News
Freshfields advises Luxinva, a wholly-owned subsidiary of the ADIA, on recommended cash acquisition of Dechra Pharmaceuticals PLC
Freshfields Bruckhaus Deringer (‘Freshfields’) is advising Luxinva – a wholly-owned subsidiary of the Abu Dhabi Investment Authority (‘ADIA’) managed by the Private Equities department of ADIA – on the recommended cash acquisition of Dechra Pharmaceuticals PLC (‘Dechra’).
The consortium is led by Swedish investment firm EQT with Luxinva as co-investor.
The announcement was issued on Friday, 2 June reflecting a recommended all cash acquisition that values Dechra at £4.46bn.
Dechra is a global veterinary pharmaceuticals and related products business and is currently listed on the London Stock Exchange.
A senior cross-border, cross-practice team at Freshfields was led by Regional Managing Partner for MENA Michael Hilton (Abu Dhabi) and partner Stephen Hewes (London), with senior associate Cheree Gemmell supporting from Abu Dhabi and associate Nikki Willson supporting from London. Antitrust advice was given by partner Rafique Bachour (Brussels) and partner Peter Clements (London) advised on tax aspects.
Further info on the transaction can be found here.
